Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TD Cowen analyst Ritu Baral downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and lowers the price target from $7...
Chardan Capital analyst Keay Nakae downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price targ...
Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighe...
RBC Capital analyst Luca Issi downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Sector Perform and raises the p...
U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acqui...
Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.
